A Multicenter, Parallel-Group, Randomized, 10-Week, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of 50 mg of DVS SR in the Treatment of Peri- and Postmenopausal Women With Major Depressive Disorder
Phase of Trial: Phase IV
Latest Information Update: 01 Aug 2014
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Pfizer; Wyeth
- 09 May 2012 Results presented at the 165th Annual Meeting of the American Psychiatric Association.
- 09 Jan 2012 Actual patient number is changed from 463 to 439 according to ClinicalTrials.gov.
- 09 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.